Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.

ABSTRACT: Diverse HPV subtypes are responsible for considerable disease burden worldwide, necessitating safe, cheap, and effective vaccines. The HPV minor capsid protein L2 is a promising candidate to create broadly protective HPV vaccines, though it is poorly immunogenic by itself. To create highly immunogenic and safe vaccine candidates targeting L2, we employed a plant-based recombinant protein expression system to produce two different vaccine candidates: L2 displayed on the surface of hepatitis B core (HBc) virus-like particles (VLPs) or L2 genetically fused to an immunoglobulin capable of forming recombinant immune complexes (RIC). Both vaccine candidates were potently immunogenic in mice, but were especially so when delivered together, generating very consistent and high antibody titers direc

SUBMITTER: Diamos AG 

PROVIDER: S-EPMC6291209 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature